Plain Language Summary What is this summary about? This is a summary of a publication about the IKEMA clinical trial that was published in The Lancet Haematology in July 2024. The trial tested if a combination of cancer drugs (isatuximab plus carfilzomib and dexamethasone, or Isa-Kd for short) would help people with relapsed (when cancer returns after a period of improvement following treatment) or refractory (when cancer stops responding to treatment) multiple myeloma live longer.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Get in touch with Meletios-Athanasios
Contact Meletios-Athanasios, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack